Pneumology and Critical Care Medicine, Thoraxklinik at University of Heidelberg, Roentgenstr. 1, Heidelberg, 69126, Germany Translational Lung Research Center Heidelberg (TLRCH), German Center for Lung Research, Heidelberg, Germany.
Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg, Heidelberg, Germany.
Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619866101. doi: 10.1177/1753466619866101.
Endoscopic valve therapy is a treatment modality in patients with advanced emphysema and absent interlobar collateral ventilation (CV). So far, long-term outcome following valve implantation has been insufficiently evaluated. The aim of this study was to investigate the real-world efficacy of this interventional therapy over 3 years.
From 2006 to 2013, 256 patients with severe emphysema in whom absent CV was confirmed underwent valve therapy. The 3-year effectiveness was evaluated by pulmonary function testing (VC, FEV, RV, TLC), 6-minute-walk test (6-MWT) and dyspnea questionnaire (mMRC). Long-term outcome was also assessed according to the radiological outcome following valve placement.
Of 256 patients treated with valves, 220, 200, 187, 100 and 66 patients completed the 3-month, 6-month, 1-year, 2-year and 3-year follow-up (FU) visit, respectively. All lung function parameters, 6-MWT and mMRC were significantly improved at 3- and 6-month FU. At 1-year FU, patients still experienced a significant improvement of all outcome parameters expect VC (L) and TLC (%). At 2 years, RV (L and %) and TLC (L and %) remained significantly improved compared to baseline. Three years after valve therapy, sustained significant improvement in mMRC was observed and the proportion of patients achieving a minimal clinically important difference from baseline in RV and 6-MWT was still 71% and 46%, respectively. Overall, patients with complete lobar atelectasis exhibited superior treatment outcome with 3-year responder rates to FEV, RV and 6-MWT of 10%, 79% and 53%, respectively.
Patients treated by valves experienced clinical improvement over 1 year following valve therapy. Afterwards, clinical benefit gradually declines more likely due to COPD progression.
内镜下阀门治疗是治疗晚期肺气肿且不存在肺叶间侧支通气(CV)的患者的一种方法。到目前为止,阀门植入后的长期效果还没有得到充分的评估。本研究的目的是在 3 年的时间里,调查这种介入治疗的真实疗效。
2006 年至 2013 年,256 例经证实不存在 CV 的严重肺气肿患者接受了阀门治疗。通过肺功能测试(VC、FEV、RV、TLC)、6 分钟步行测试(6-MWT)和呼吸困难问卷(mMRC)评估 3 年的有效性。根据阀门放置后的影像学结果评估长期结果。
256 例接受阀门治疗的患者中,分别有 220、200、187、100 和 66 例患者完成了 3 个月、6 个月、1 年、2 年和 3 年的随访(FU)。所有的肺功能参数、6-MWT 和 mMRC 在 3 个月和 6 个月的 FU 时均显著改善。在 1 年的 FU 时,患者除了 VC(L)和 TLC(%)外,所有的结局参数仍有显著改善。在 2 年时,RV(L 和%)和 TLC(L 和%)与基线相比仍有显著改善。阀门治疗 3 年后,mMRC 仍保持显著改善,RV 和 6-MWT 达到最小临床重要差异的患者比例仍分别为 71%和 46%。总体而言,完全性肺叶萎陷的患者在 3 年内对治疗的反应更好,FEV、RV 和 6-MWT 的 3 年反应率分别为 10%、79%和 53%。
接受阀门治疗的患者在阀门治疗后 1 年内经历了临床改善。之后,由于 COPD 的进展,临床获益逐渐下降。